Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN 7% (PH6) vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and metabolic processes, providing essential and non-essential amino acids for tissue repair and maintenance.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
AminoSyn 7% (pH 6) is administered intravenously as a component of parenteral nutrition. The typical adult dose is 1.0-1.5 g amino acids/kg/day, infused at a rate not exceeding 0.1 g amino acids/kg/hour. The infusion rate and volume are determined by the patient's metabolic needs, clinical status, and concurrent dextrose and lipid administration.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
The elimination half-life of individual amino acids varies, typically 0.5-2 hours for most, reflecting rapid incorporation into metabolic pools. For total amino acid mixture, functional half-life is approximately 1-2 hours in patients with normal hepatic and renal function.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Amino acids in Aminosyn 7% (pH6) are primarily metabolized; excess nitrogen is excreted renally as urea. Approximately 80-90% of infused amino acids are utilized for protein synthesis or metabolized; remaining nitrogen is eliminated as urea via kidneys. Biliary and fecal elimination are negligible.
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution